$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
帕博西尼与来曲唑联合用于治疗绝经后ER阳性/HER2阴性进展期转移性乳腺癌
2025-10-19 11:44:20
Check Details
玻玛西林适用于激素受体阳性(HR+)和HER2阴性(HER2-)的乳腺癌的治疗
2025-10-19 11:44:20
Check Details
帕博西尼与氟维司群联合用于内分泌治疗后进展的ER阳性/HER2阴性乳腺癌
2025-10-19 11:44:20
Check Details
乳腺癌患者用玻玛西林可以延长多久的生存期?
2025-10-19 11:44:20
Check Details
全球首个批准上市的CDK4/6激酶抑制剂-帕博西尼
2025-10-19 11:44:20
Check Details
玻玛西林治疗单药治疗HR + / HER2-转移性乳腺癌的效果
2025-10-19 11:44:20
Check Details
抗癌药帕博西尼对乳腺癌患者有着较好的疗效
2025-10-19 11:44:20
Check Details
乳腺癌靶向药帕博西尼售价贵吗?在哪买的到?
2025-10-19 11:44:20
Check Details
玻玛西林联合含芳香酶抑制剂的治疗效果
2025-10-19 11:44:20
Check Details
玻玛西林的出现,使乳腺癌患者有了新选择
2025-10-19 11:44:20
Check Details
乳腺癌脑转移适合使用帕博西尼进行治疗吗?
2025-10-19 11:44:20
Check Details
乳腺癌患者使用玻玛西林治疗可以使肿瘤缩小吗?
2025-10-19 11:44:20
Check Details
1
2
...
8069
8070
8071
8072
8073
8074
8075
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
2
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
3
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
4
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
7
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
8
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
11
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks